Description
A2b543 is a mesothelin-targeting logic-gated CAR T cell therapy designed for solid tumors expressing mesothelin (MSLN). This engineered cellular immunotherapy utilizes the patient's own T cells, which are genetically modified to recognize and attack cancer cells that display mesothelin on their surface. In colorectal cancer, this therapy targets the subset of tumors that express mesothelin, a protein found on various solid tumor types.
Mechanism of Action
The therapy works through chimeric antigen receptor (CAR) T cells that have been engineered with logic-gating technology to specifically recognize mesothelin-expressing cancer cells. Once the modified T cells encounter mesothelin on tumor cells, they become activated and mount a targeted immune response against the cancer, leading to tumor cell destruction through cytotoxic mechanisms.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
| Administration | IV |
| Clinical Trials | 1 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.